"Though the decision to screen or not to screen needs to be individualized for each patient, the potential to detect the disease early offers the best chance of cure. There have been significant concerns about the impact screening will have on our health system and without question its introduction will be complex and require a multidisciplinary approach," said Mark Dransfield, M.D., associate professor, division of pulmonary, allergy and critical care medicine at the University of Alabama at Birmingham. He is also the medical director of the UAB Lung Health Center.
New research conducted at the University of Alabama at Birmingham has shown that the common blood pressure drug verapamil completely reverses type 1 diabetes in animal models. Now, with the help of a three-year, $2.1 million grant from the JDRF, UAB researchers will begin conducting a clinical trial in 2015 to see if it can do the same in humans.
"Crowdfunding is a remarkable tool for making big ideas a reality," Shirley Salloway Kahn, UAB senior vice president of development, alumni and external relations, said in the release. "Everyone can play a role in making history at UAB in ways big and small. With just a click, you can give something and change everything."